Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Simeprevir - Medivir/Janssen R&D Ireland

Drug Profile

Simeprevir - Medivir/Janssen R&D Ireland

Alternative Names: Galexos; JNJ-38733214-AAA; Olysio; R-494617; SMV; Sovriad; TMC-435; TMC-435350

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medivir AB
  • Developer Alios BioPharma; Janssen Pharmaceutical KK; Janssen R&D Ireland; Medivir AB
  • Class 3-ring heterocyclic compounds; Antivirals; Cyclopropanes; Quinolines; Small molecules; Sulfonamides; Thiazoles
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 May 2018 Phase-II clinical trials in Hepatitis C (Combination therapy) in Mauritius, Moldova (PO) before May 2018 (NCT02569710)
  • 11 May 2018 Alios Biopharma completes a phase II trial in Hepatitis C in New Zealand, Moldova, Mauritius, United Kingdom (NCT02569710)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top